Logan Reed
The United States has never used mass immunization of the bacille Calmette-Guérin (BCG) vaccine due to the rarity of tuberculosis (TB) in the country. Instead, the US relies on the detection and treatment of latent TB. The BCG vaccine is no longer routinely given in the US and is not recommended for the general population, according to the Centers for Disease Control and Prevention (CDC). However, it may still be considered for children and adults with a high risk of tuberculosis exposure, such as those with certain risk factors or those planning to travel to a country with high TB rates. The vaccine is more commonly used in other countries where TB is more frequent.
| Characteristics | Values |
|---|---|
| Whether the US stopped vaccinating for TB | The US has never used mass immunization of BCG due to the rarity of tuberculosis in the country. |
| Reasons for not vaccinating | Tuberculosis is rare in the US, and the country relies on detection and treatment of latent tuberculosis. |
| Current recommendations | The BCG vaccine is not generally used in the US, but it may be recommended for children with a high risk of tuberculosis exposure, such as those living with someone infected with TB. |
| Effectiveness | The vaccine is effective in protecting against severe forms of TB in young children but is less effective in preventing lung infections commonly found in adolescents and adults. |
| Side effects | The vaccine has no serious side effects, but it can cause a false positive TB skin test reaction. |
| Global usage | Many countries worldwide still use the BCG vaccine, especially in areas where TB is common. |
Explore related products
What You'll Learn
The US never used mass TB immunisation
The US has never implemented mass TB immunisation due to the rarity of tuberculosis in the country. Instead, it relies on the detection and treatment of latent tuberculosis. The tuberculosis vaccine, also known as the bacille Calmette-Guérin (BCG) vaccine, is no longer routinely given in the United States and is not recommended for the general population. However, it is still administered to infants and young children in many countries worldwide, including Canada, Central and South America, Mexico, China, Japan, and several Southeast Asian countries.
In the US, the BCG vaccine may be considered for certain individuals with significant risk factors for prolonged exposure to TB, such as healthcare workers and children regularly cared for by adults with drug-resistant TB or untreated TB. The vaccine is also sometimes used to treat bladder cancer and tumours. Recent research suggests that the BCG vaccine is most effective in preventing severe disease in children under five years old. Among older children and adults, the vaccine may not offer reliable protection against TB disease and its related complications.
The BCG vaccine was developed in the early 1900s by researchers Albert Calmette and Camille Guérin to protect against tuberculosis. It was in wide use in parts of Europe, like France and Germany, by the 1920s. The vaccine is safe and has been thoroughly tested and vetted for safety. However, evidence of its effectiveness in protecting against TB is mixed. While it is effective in preventing severe forms of TB in young children, it is less effective in preventing lung infections commonly found in adolescents and adults.
In the United States, the spread of TB is controlled through regular skin tests, such as the TST or PPD, to identify individuals infected with TB. Once identified, those with TB are treated with antibiotics such as isoniazid (INH), rifampin, ethambutal, or pyrazinamide. Additionally, the incidence of tuberculosis in the US has been slowly declining since 1993, likely due to better control of HIV with the use of anti-retroviral drugs. Despite this decline, predictions suggest that tuberculosis will likely not be eliminated from the United States during this century.
Influenza Vaccine Options for Seniors Over 65
You may want to see also
Explore related products
The TB vaccine is rarely used in the US today
The bacille Calmette-Guérin (BCG) vaccine, or tuberculosis (TB) vaccine, is rarely used in the US today. The vaccine is safe but evidence of its effectiveness in protecting against TB is mixed. While the BCG vaccine is routinely administered to newborns and young children in many countries worldwide, the US has never used mass immunisation of BCG due to the rarity of tuberculosis in the country. Instead, it relies on the detection and treatment of latent tuberculosis.
The TB vaccine is good at protecting against the severe form of the disease found in young children (called "miliary" TB), but it is not as effective at preventing the lung infection commonly found in adolescents and adults. Miliary TB is very uncommon in the US, so the TB vaccine is not routinely used. The US is one of only two countries that have never routinely used the TB vaccine, the other being the Netherlands.
The TB vaccine is only recommended for a small subset of people who are in close contact with someone infected with TB. Specifically, someone in constant contact with an infected person who either refuses to take antibiotics or is infected with a strain that is resistant to all antibiotics. The vaccine may also be considered for children and adults with a high risk of TB exposure, such as healthcare workers and children cared for by adults with drug-resistant TB.
Recent research suggests that the TB vaccine is only significantly effective in preventing severe disease in children under five years old. Among kids aged five and above who haven't had a positive TB test, studies indicate that the BCG vaccination doesn't offer reliable protection against TB disease and related complications. The CDC states that the BCG vaccine is not generally used in the US, and it is not recommended for the general population.
Chickenpox Vaccine: What's Its Name?
You may want to see also
Explore related products
The TB vaccine is recommended for children at high risk of infection
The bacille Calmette-Guérin (BCG) vaccine, or tuberculosis (TB) vaccine, is used to protect against TB and related complications. While the BCG vaccine is no longer routinely given in the United States and is not recommended for the general population, it is still administered to babies and young children in many countries.
The TB vaccine is specifically recommended for children at high risk of infection. This includes children who are regularly in close contact with adults infected with TB, especially if the child or the adult they are in contact with has a weakened immune system. For example, children who live with adults who have untreated, ineffectively treated, or drug-resistant TB may benefit from the vaccine. Additionally, children with weakened immune systems, such as those with a family history of HIV or severe combined immunodeficiency (SCID), may also be considered for the vaccine.
The BCG vaccine is most effective in babies and children under five, as it helps protect against severe forms of TB, such as TB meningitis. Older children and adults may not benefit as much from receiving the vaccine, although people of all ages with certain risk factors may still be considered for vaccination. In countries where the BCG vaccine is routinely administered, it is typically given to newborns just after birth or within the first month of life.
In the United States, the decision to administer the TB vaccine to children at high risk of infection is made in consultation with a local TB control program. Before receiving the vaccine, individuals may undergo a tuberculin skin test or blood test to determine their TB status. The TB vaccine is generally safe and has no serious side effects, but evidence of its effectiveness in protecting against TB is mixed.
Hepatitis B Vaccination: Why Am I Still at Risk?
You may want to see also
Explore related products
The TB vaccine is not effective for everyone
The United States has never used mass immunization of the tuberculosis (TB) vaccine, also known as the bacille Calmette-Guérin (BCG) vaccine, due to the rarity of tuberculosis in the country. The vaccine is no longer routinely given in the US and is not recommended for the general population. However, it is still administered to individuals with a high risk of tuberculosis exposure, such as healthcare workers and children regularly in contact with adults who have tuberculosis.
The BCG vaccine is a live vaccine that uses a weakened strain of Mycobacterium bovis, a bacterium closely related to the one that causes TB. While the vaccine is generally safe, evidence of its effectiveness in protecting against TB is mixed. Recent research suggests that the vaccine is only significantly effective in preventing severe disease in children under five. In older children and adults, the BCG vaccine may not provide reliable protection against TB and its related complications. This variable efficacy of the BCG vaccine has been attributed to several factors, including the BCG strain and previous exposure to environmental mycobacteria.
The masking hypothesis, supported by studies in London and Malawi, suggests that prior immunity induced by non-tuberculous mycobacteria can mask or inhibit the effects of the BCG vaccine. The blocking hypothesis, based on mouse studies, indicates that immunity against mycobacteria prevents the BCG vaccine from replicating and producing an adequate immune response. Additionally, concurrent parasitic infections can alter the immune response to BCG, reducing its effectiveness.
Furthermore, the BCG vaccine is not suitable for everyone. It is not recommended for individuals who have previously tested positive for TB or those with a weakened immune system, such as individuals with HIV or undergoing immunosuppressive treatments. In rare cases, the BCG vaccine can cause serious complications like regional bone infection and disseminated BCG infection.
While the BCG vaccine has been shown to offer partial protection against TB, scientists are still working towards developing a more effective vaccine. The challenge lies in creating a vaccine that elicits a faster and more robust immune response to eradicate or prevent TB infection.
Hep B Vaccine: Who Pays When Employers Require It?
You may want to see also
Explore related products
$25.99 $31.98
$25.49 $29.99
The TB vaccine is used to treat bladder cancer
The bacillus Calmette-Guerin (BCG) vaccine, or tuberculosis (TB) vaccine, is used to prevent TB infection and complications. The BCG vaccine is a live vaccine that uses a weakened strain of Mycobacterium bovis, a bacterium closely related to the one that causes TB. While the BCG vaccine is routinely administered to infants and young children in many countries, it is no longer widely used in the United States due to the rarity of tuberculosis in the country.
The TB vaccine, or BCG treatment, is also used to treat early-stage bladder cancer. It is delivered directly into the bladder through a catheter, stimulating the body's immune response to fight cancer. This process is called intravesical immunotherapy, and it has been used since the 1980s. BCG treatment is typically given after bladder surgery to remove visible cancer and is most effective for cancers that have not invaded the bladder wall muscle.
During BCG treatment, a liquid form of the vaccine is injected into the bladder through a catheter. The patient is advised to hold their urine for at least one hour, and ideally for two hours, to allow the medication to remain in the bladder. The treatment activates the immune system cells in the bladder, which then attack the cancer cells.
BCG treatment is generally well-tolerated, but it can cause side effects such as flu-like symptoms, a burning feeling in the bladder, and the need to urinate frequently. In rare cases, serious BCG infections can occur, particularly in individuals with weakened immune systems. It is important to note that BCG treatment is not effective against bladder cancer that has metastasized or spread to other parts of the body.
While the TB vaccine has proven effective in treating bladder cancer, it is important to consult a healthcare provider for specific recommendations and to explore the latest clinical advancements in cancer treatment.
Rubella Vaccination: Why Am I Still Susceptible?
You may want to see also
Frequently asked questions
The US has never used mass immunization of the BCG vaccine due to the rarity of tuberculosis in the country.
The BCG vaccine is not generally used in the US because it is not very effective at preventing lung infections caused by the tuberculosis bacteria. Instead, the US relies on the detection and treatment of latent tuberculosis.
The BCG vaccine is only recommended for children living with someone who is infected with TB and cannot take antibiotics or is infected with a strain of TB that is resistant to antibiotics.
